Raseglurant (
INN
Inns are generally establishments or buildings where travelers can seek lodging, and usually, food and drink. Inns are typically located in the country or along a highway; before the advent of motorized transportation they also provided accommo ...
) (code name ADX-10059) is a
negative allosteric modulator of the
mGlu5 receptor and
derivative
In mathematics, the derivative of a function of a real variable measures the sensitivity to change of the function value (output value) with respect to a change in its argument (input value). Derivatives are a fundamental tool of calculus. ...
of
MPEP which was under development by
Addex Therapeutics for the treatment of
migraine
Migraine (, ) is a common neurological disorder characterized by recurrent headaches. Typically, the associated headache affects one side of the head, is pulsating in nature, may be moderate to severe in intensity, and could last from a few ho ...
,
gastroesophageal reflux disease
Gastroesophageal reflux disease (GERD) or gastro-oesophageal reflux disease (GORD) is one of the upper gastrointestinal chronic diseases where stomach content persistently and regularly flows up into the esophagus, resulting in symptoms and/ ...
, and
dental anxiety.
It reached
phase II Phase II, Phase 2 or Phase Two may refer to:
Media
* Marvel Cinematic Universe: Phase Two, six American superhero films from 2013–2015
* ''Star Trek: Phase II'', an unrealized television series based on the characters of Gene Roddenberry's ''S ...
clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human subject research, human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel v ...
s for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of
hepatotoxicity
Hepatotoxicity (from ''hepatic toxicity'') implies chemical-driven liver damage. Drug-induced liver injury is a cause of acute and chronic liver disease caused specifically by medications and the most common reason for a drug to be withdrawn fr ...
in patients with long-term use.
See also
*
Basimglurant
*
Dipraglurant
Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). As of 2014, it is ...
*
Fenobam
*
Mavoglurant
Mavoglurant (developmental code name AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome and other conditions which has been discontinued. It exerts its effect as an antagonist of the metabotropic glutamate receptor ...
References
External links
Development of ADX10059 Ended for Long-term Use - Addex Therapeutics
MGlu5 receptor antagonists
Fluoroarenes
Aminopyridines
Alkyne derivatives
{{nervous-system-drug-stub